Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more

Recent & Breaking News (NDAQ:ALDX)

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results

PR Newswire August 1, 2017

Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial

PR Newswire July 18, 2017

Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting

PR Newswire June 19, 2017

10 Biggest Mid-Day Losers For Wednesday

Benzinga.com  June 14, 2017

Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing

PR Newswire June 14, 2017

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial

PR Newswire June 13, 2017

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial

PR Newswire June 6, 2017

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

Marketwired May 17, 2017

Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results

Marketwired May 15, 2017

Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call

Accesswire May 15, 2017

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results

Marketwired May 8, 2017

Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial

Marketwired April 27, 2017

Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome

Marketwired April 20, 2017

Aldeyra Therapeutics Reports Full Year 2016 Financial Results

Marketwired March 30, 2017

Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results

Marketwired March 22, 2017

Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

Marketwired February 28, 2017

Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome

Marketwired February 22, 2017

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Marketwired February 17, 2017

Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock

Marketwired February 14, 2017

Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock

Marketwired February 13, 2017